Valneva
Petronela Weisova PhD is currently working as the Sn.Clinical Strategy/Sn.Clinical Science Lead at Valneva, specializing in Chickungunya vaccine clinical development. Petronela also played a crucial role in the market authorization of the COVID-19 vaccine VLA2001. With a background in neuroimmunology and neurodegeneration, Petronela has extensive experience in academic-industry collaborations, clinical project management, and pre-clinical research in Alzheimer's disease and tauopathies. Petronela's expertise also includes clinical diagnostics for avian influenza and molecular neuroscience.
This person is not in any offices
Valneva
3 followers
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.